Edition:
India

People: ARCA Biopharma Inc (ABIO.OQ)

ABIO.OQ on NASDAQ Stock Exchange Capital Market

5.30USD
9 Dec 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.30
Open
$5.35
Day's High
$5.43
Day's Low
$5.25
Volume
10,982
Avg. Vol
16,655
52-wk High
$20.40
52-wk Low
$4.72

Bristow, Michael 

Dr. Michael R. Bristow Ph.D., M.D is President, Chief Executive Officer, Director of ARCA biopharma Inc. Prior to that time, Dr. Bristow served as the Company’s Chief Science and Medical Officer and a director since the merger with Nuvelo. Dr. Bristow has also served as a director of ARCA Colorado since November 2006. Dr. Bristow was one of the founders of ARCA Colorado in September 2004, and served as its Chairman and Chief Executive Officer from that date until he was appointed to the position of Chief Science and Medical Officer in November 2006. Dr. Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr. Bristow was one of the founders of Myogen, Inc. and served as Myogen’s Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006. Dr. Bristow also has experience with and knowledge of ARCA’s business, as the founder and former Chief Science and Medical Officer of ARCA Colorado, and the current President and Chief Executive Officer of the Company, and as a Board member of ARCA Colorado since 2005, and of the Company since January 2009.

Basic Compensation

Total Annual Compensation, USD 300,664
Restricted Stock Award, USD 110,565
Long-Term Incentive Plans, USD --
All Other, USD 90,171
Fiscal Year Total, USD 501,400

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --